

# IOL Chemicals and Pharmaceuticals Limited

## UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/ NINE MONTHS ENDED DECEMBER 31, 2009

(Rs. in lacs)

Sr. No.	Particulars	Quarter ended		Nine Months ended		Year ended 31.03.2009 (Audited)
		31.12.2009	31.12.2008	31.12.2009	31.12.2008	
1	a) Net Sales / Income from operations	8597.26	6732.49	26302.82	23012.31	30185.85
	b) Other operating income	25.12	43.79	80.95	60.26	331.71
	Total ( 1 )	8622.38	6776.28	26383.77	23072.57	30517.56
2	Expenditure					
	a) ( increase ) / decrease in stock in trade	404.17	(698.24)	(193.22)	(1210.36)	(1370.78)
	b) Consumption of raw materials	5406.57	5517.52	17654.79	17274.50	22298.56
	c) Purchase of traded goods	--	--	611.96	--	--
	d) Employees cost	288.35	165.09	831.59	591.84	813.81
	e) Depreciation	251.64	253.32	760.05	752.46	1000.17
	f) Other expenditure	1245.21	1100.70	4564.32	3746.92	5175.88
	Total ( 2 )	7595.94	6338.39	24229.49	21155.36	27917.64
3	Profit from operations before other income, interest and exceptional items ( 1-2 )	1026.44	437.89	2154.28	1917.21	2599.92
4	Other income	0.45	0.45	1.35	1.35	1.80
5	Profit before interest and exceptional items (3+4)	1026.89	438.34	2155.63	1918.56	2601.72
6	Interest	388.06	316.05	1097.26	1092.77	1491.95
7	Profit after interest but before exceptional items (5-6)	638.83	122.29	1058.37	825.79	1109.77
8	Exceptional items	--	--	--	--	--
9	Profit from ordinary activities before tax (7+8)	638.83	122.29	1058.37	825.79	1109.77
10	Tax Expenses	--	36.49	1.20	132.28	(159.65)
11	Net Profit from ordinary activities after tax (9-10)	638.83	85.80	1057.17	693.51	1269.42
12	Extraordinary Item (net of tax expense)	--	--	--	--	--
13	Net Profit for the period (11-12)	638.83	85.80	1057.17	693.51	1269.42
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	2121.67	1769.60	2121.67	1769.60	1815.00
15	Reserves excluding revaluation reserves	--	--	--	--	7939.30
16	Earning per share (not annualized)					
	- Basic	3.04	0.58	5.04	4.71	8.18
	- Diluted	3.04	0.49	5.04	3.92	7.87
17	Public shareholding					
	- No of shares	10276611	8182047	10276611	8182047	8412047
	- % age	48.44	46.24	48.44	46.24	46.35
18	Promoters and promoter group shareholding					
	a) Pledged/encumbered					
	- Number of shares	400000	400000	400000	400000	400000
	- %age of the total promoters' shareholding	3.66	4.20	3.66	4.20	4.11
	- % age of the total shareholding	1.88	2.26	1.88	2.26	2.20
	b) Non-encumbered					
	- Number of shares	10540053	9113953	10540053	9113953	9337953
	- %age of the total promoters' shareholding	96.34	95.80	96.34	95.80	95.89
	- % age of the total shareholding	49.68	51.50	49.68	51.50	51.45

**Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement**

(Rs. in Lacs)

Sr. No	Particulars	Quarter ended		Nine Months ended		Year ended 31.03.2009 (Audited)
		31.12.2009	31.12.2008	31.12.2009	31.12.2008	
1	Segment Revenue (Net sales/income)					
	- Chemicals	5300.18	4700.91	17847.44	16647.12	21292.58
	- Drugs	3256.07	2022.13	8382.70	6300.48	8791.08
	- Unallocated	66.13	53.24	153.63	124.97	433.90
	Total	8622.38	6776.28	26383.77	23072.57	30517.56
	Less : Inter segment revenue	--	--	--	--	--
	Net sales/income from operations	8622.38	6776.28	26383.77	23072.57	30517.56
2	Segment Results					
	Profit/(loss) before tax and interest from each segment)					
	- Chemicals	537.42	148.58	1274.50	1392.97	1663.99
	- Drugs	461.88	236.07	798.60	399.29	560.87
	Total	999.30	384.65	2073.10	1792.26	2224.86
	Less :					
	Interest	388.06	316.05	1097.26	1092.77	1491.95
	Other un-allocable expenditure net off un-allocable income	(27.59)	(53.69)	(82.53)	(126.30)	(376.86)
	Total Profit before tax & Extraordinary Items	638.83	122.29	1058.37	825.79	1109.77
3	Capital Employed (Segment assets - Segment liabilities)					
	- Chemicals	7307.51	5652.22	7307.51	5652.22	6130.82
	- Drugs	8282.52	8498.49	8282.52	8498.49	8159.92
	- Unallocated including capital work in progress	27039.90	16812.98	27039.90	16812.98	21821.42
	Total	42629.93	30963.69	42629.93	30963.69	36112.16

**Notes:**

1. Status of Investor Complaints for the quarter ended December 31, 2009 is as under:

Complaints at the beginning of quarter	Complaints received during the quarter	Complaints resolved	Complaints pending
Nil	Nil	Nil	Nil

2. The company has issued 15 lac equity shares and 30 lac share warrants to the promoters on 16<sup>th</sup> January 2010.
3. The ongoing expansion cum backward and forward integration project has been implemented and the Company has incurred Rs 258 Crores on the ongoing projects up to December 31, 2009.
4. Deferred Tax provision will be made at the time of finalization of annual accounts.
5. The figures of previous quarter/ year have been regrouped/ rearranged wherever necessary.
6. The above results have been reviewed by the Audit & Risk Management Committee and taken on record by the Board of the Directors at their meeting held on January 30, 2010 and limited review of the same has been carried out by the Statutory Auditors of the Company.

**By order of the Board**

For IOL Chemicals and Pharmaceuticals Limited

Sd/-

(Varinder Gupta)

Chairman and Managing Director

Place: Ludhiana

Date: January 30, 2010